SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wiseman H. Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention. New York: John Wiley & Sons, 1994.
  • 2
    Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 1998; 90: 1371 88.
  • 3
    Boix L, Bruix J, Castells A et al. Sex hormones in hepatocellular carcinoma. Is there rationale for hormonal treatment? J. Hepatol. 1993; 17: 187 91.
  • 4
    Friedman MA, Demanes DJ, Hoffman Jr PG. Hepatomas: hormone receptors and therapy. Am. J. Med. 1982; 73: 362 6.
  • 5
    Ng IO, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am. J. Gastroenterol. 1997; 92: 1355 8.
  • 6
    Jonas S, Bechstein WO, Heinze T et al. Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection. Surgery 1997; 121: 456 61.
  • 7
    Engstrom PF, Levin B, Moertel CG, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 1990; 65: 2641 3.
  • 8
    Farinati F, Salvagnini M, Maria N et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J. Hepatol. 1990; 11: 297 301.
  • 9
    Martinez Cerezo FJ, Tomas A, Donoso L et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J. Hepatol. 1994; 20: 702 6.
  • 10
    Castells A, Bruix J, Bru C et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917 22.
  • 11
    CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998; 352: 17 20.
  • 12
    Chow P, Tan CK, Tai BC, Machin D. Tamoxifen in hepatocellular carcinoma (letter). Lancet 1998; 352: 819 20.
  • 13
    Riestra S, Rodriguez M, Delgado M et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J. Clin. Gastroenterol. 1998; 26: 200 3.
  • 14
    Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital. J. Gastroenterol. 1994; 26: 66 8.
  • 15
    Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat. Rep. 1987; 71: 1213 16.
  • 16
    Uchino J, Une Y, Sato Y, Gondo H, Nakajima Y, Sato N. Chemohormonal therapy of unresectable hepatocellular carcinoma. Am. J. Clin. Oncol. 1993; 16: 206 9.
  • 17
    Farinati F, De Maria N, Marafin C et al. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolisation. Dig. Dis. Sci. 1996; 41: 2332 9.
  • 18
    Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomised, controlled trial. Hepatology 1995; 21: 1535 42.
  • 19
    Maffei FA, Gerunda GE, Neri D et al. [The palliative treatment of hepatocarcinoma: chemoembolisation vs the combination of tamoxifen plus beta-interferon]. Chir. Ital. 1994; 46: 12 16.
  • 20
    Kountouras J, Boura P, Karolides A, Zaharioudaki E, Tsapas G. Recombinant α2 interferon (α-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). Hepatogastroenterology 1995; 42: 31 6.
  • 21
    Villa E, Dugani A, Fantoni E et al. Type of estrogen receptor determines response to anti-oestrogen therapy. Cancer Res. 1996; 56: 3883 5.
  • 22
    Berridge MJ & Irving RF. Inositol triphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 321: 315 21.
  • 23
    Oíbrian CA, Liskamp RM, Solomon DH, Weinstein IB. Inhibition of protein kinase C by tamoxifen. Cancer Res. 1985; 45: 2462 5.
  • 24
    Su HD, Mazzei GJ, Vogler WR, Kuo JF. Effect of tamoxifen, a non-steroidal antioestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem. Pharmacol. 1985; 34: 3649 53.
  • 25
    Edashie K, Sato EF, Akimaru K, Yoshioka T, Utsumi K. Nonsteroidal anti-oestrogen suppresses protein kinase C. Its inhibitory effect on interaction of substrate protein with membrane. Cell Struct. Funct. 1991; 16: 273 81.
  • 26
    Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick Jr FT. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res. 1990; 50: 7134 8.
  • 27
    Lam H-YP. Tamoxifen is a calmodulin antagonist in the activation of a cAMP phosphodiesterase. Biochem. Biophys. Res. Commun. 1984; 118: 27 32.
  • 28
    Gulino A, Barrera G, Vacca A et al. Calmodulin antagonism and growth inhibitory activity of triphenylethylene antioestrogens in MCF-7 human breast cancer cells. Cancer Res. 1986; 46: 6274 8.
  • 29
    Rowlands MG, Parr IB, MacCague R, Jarman M, Goddard PM. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase among analogues of tamoxifen: Correlation with cytotoxicity. Biochem. Pharmacol. 1990; 40: 283 9.
  • 30
    Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem. Pharmacol. 1995; 50: 723 6.
  • 31
    Colletta AA, Wakefield LM, Howell FV et al. Anti-oestrogens induce the secretion of active transforming growth factor. Br. J. Cancer 1990; 62: 405 9.
  • 32
    Butta A, MacLennan K, Flanders KC et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992; 52: 4261 4.
  • 33
    Nakamura T, Tomita Y, Hirai R, Yamaoka K, Kaji K, Ichihara A. Inhibitory effect of transforming growth factor β on DNA synthesis of adult rat hepatocytes in primary culture. Biochem. Biophys. Res. Commun 1985; 133: 1042 50.
  • 34
    Hung WC, Chang HC, Chuang LY. Transforming growth factor beta 1 potently activates CPP32-like proteases in human hepatoma cells. Cell Signal 1998; 10: 511 15.
  • 35
    Wiseman H, Quinn P, Halliwell B. Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions? FEBS Lett. 1993; 330: 53 6.
  • 36
    Houslay MD. Regulation of adenylate cyclase (EC 4.6.I.I) activity by its lipid environment. Proc. Nutr. Soc. 1985; 44: 157 65.
  • 37
    Galeotti T, Borrello S, Palombini G et al. Lipid peroxidation and fluidity of plasma membranes from rat liver and Morris hepatoma 3924A. FEBS Lett. 1984; 169: 169 73.
  • 38
    Jiang SY, Shyu RY, Yeh MY, Jordan VC. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J. Hepatol. 1995; 23: 712 19.
  • 39
    Cheng AL, Chuang SE, Fine RL et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem. Pharmacol. 1998; 55: 523 31.
  • 40
    Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin. Oncol. 1997; 24: S1-65 70.
  • 41
    Vertosick FtJr, Selker RG, Pollack IF, Arena V. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of ëfailedí patients. Neurosurgery 1992; 30: 897 902.
  • 42
    Couldwell WT, Weiss MH, DeGiorgio CM et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32: 485 9.